Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Long, Georgina V, MD, Stroyakovskiy, Daniil, MD, Gogas, Helen, MD, Levchenko, Evgeny, MD, de Braud, Filippo, MD, Larkin, James, FRCP, Garbe, Claus, Prof, Jouary, Thomas, MD, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Lebbe, Celeste, Prof, Mandalà, Mario, MD, Millward, Michael, Prof, Arance, Ana, MD, Bondarenko, Igor, Prof, Haanen, John B A G, Prof, Hansson, Johan, Prof, Utikal, Jochen, Prof, Ferraresi, Virginia, MD, Kovalenko, Nadezhda, Prof, Mohr, Peter, MD, Probachai, Volodymr, MD, Schadendorf, Dirk, Prof, Nathan, Paul, MD, Robert, Caroline, MD, Ribas, Antoni, Prof, DeMarini, Douglas J, PhD, Irani, Jhangir G, MA, Swann, Suzanne, PhD, Legos, Jeffrey J, PhD, Jin, Fan, MD, Mookerjee, Bijoyesh, MD, Flaherty, Keith, MD
Published in The Lancet (British edition) (01.08.2015)
Published in The Lancet (British edition) (01.08.2015)
Get full text
Journal Article
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Grob, Jean Jacques, Prof, Amonkar, Mayur M, PhD, Karaszewska, Boguslawa, MD, Schachter, Jacob, Prof, Dummer, Reinhard, Prof, Mackiewicz, Andrzej, Prof, Stroyakovskiy, Daniil, MD, Drucis, Kamil, MD, Grange, Florent, MD, Chiarion-Sileni, Vanna, MD, Rutkowski, Piotr, Prof, Lichinitser, Mikhail, Prof, Levchenko, Evgeny, MD, Wolter, Pascal, MD, Hauschild, Axel, Prof, Long, Georgina V, MD, Nathan, Paul, MD, Ribas, Antoni, Prof, Flaherty, Keith, MD, Sun, Peng, PhD, Legos, Jeffrey J, PhD, McDowell, Diane Opatt, MD, Mookerjee, Bijoyesh, MD, Schadendorf, Dirk, Prof, Robert, Caroline, MD
Published in The lancet oncology (01.10.2015)
Published in The lancet oncology (01.10.2015)
Get full text
Journal Article
Cobimetinib combined with vemurafenib in advanced BRAFV600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Ascierto, Paolo A, MD, McArthur, Grant A, Prof, Dréno, Brigitte, Prof, Atkinson, Victoria, MD, Liszkay, Gabrielle, MD, Di Giacomo, Anna Maria, MD, Mandalà, Mario, MD, Demidov, Lev, MD, Stroyakovskiy, Daniil, MD, Thomas, Luc, Prof, de la Cruz-Merino, Luis, MD, Dutriaux, Caroline, MD, Garbe, Claus, Prof, Yan, Yibing, PhD, Wongchenko, Matthew, BS, Chang, Ilsung, PhD, Hsu, Jessie J, PhD, Koralek, Daniel O, PhD, Rooney, Isabelle, MBChB, Ribas, Antoni, Prof, Larkin, James, FRCP
Published in The lancet oncology (01.09.2016)
Published in The lancet oncology (01.09.2016)
Get full text
Journal Article